• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: Neuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Completion of Acquisition or Disposition of Assets

    3/27/25 4:35:12 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    0001227636trueThis Amendment No. 1 on Form 8-K/A (this "Amendment") is filed to provide updates to the Company's financial results for the three months and year ending December 31, 2024 included in the Original Form 8-K as described in Item 2.02 and Item 7.01 below.00012276362025-03-042025-03-04

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

     

    FORM 8-K/A 

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of The Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) March 27, 2025 (March 4, 2025) 

     

     

    NEURONETICS, INC. 

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    001-38546

     

    33-1051425

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    ​

     

    3222 Phoenixville Pike, Malvern, PA

     

    19355

    (Address of principal executive offices)

     

    (Zip Code)

    Registrant’s telephone number, including area code (610) 640-4202 

    (Former name or former address, if changed since last report.) Not applicable.

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ​

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

    ​

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

    ​

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol (s)

     

    Name on each exchange

    on which registered

    Common Stock ($0.01 par value)

     

    STIM

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

    Emerging growth company ☐ 

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    Explanatory Note

    ​

    On March 4, 2025, Neuronetics Inc. (the “Company”) issued a press release setting forth the Company’s preliminary financial results and other information for the three months and year ending December 31, 2024 (the “Fourth Quarter 2024 Earnings Release”) and released an investor presentation that included selected financial results and other information for the three months and year ending December 31, 2024 (the “Fourth Quarter 2024 Presentation”). The Fourth Quarter 2024 Earnings Release and the Fourth Quarter 2024 Presentation were furnished on a Form 8-K filed on March 4, 2025 (the “Original Form 8-K”). This Amendment No. 1 on Form 8-K/A (this “Amendment”) is filed to provide updates to the Company’s financial results for the three months and year ending December 31, 2024 included in the Original Form 8-K as described in Item 2.02 and Item 7.01 below.

    ​

    Item 2.02 Results of Operations and Financial Condition.

    ​

    On March 4, 2025, the Company issued the Fourth Quarter 2024 Earnings Release. A copy of the press release was furnished as Exhibits 99.1 to the Original Form 8-K. Following the Fourth Quarter 2024 Earnings Release and in connection with finalizing the audited financial statements for the fiscal year ending December 31, 2024, certain non-cash revisions were made to the preliminary financial statements related to acquisition of Greenbrook TMS Inc. (“Greenbrook”) and the shares outstanding in the fourth quarter of 2024. The Company issued a press release on March 27, 2025 announcing its updated financial results for the three months ended December 31, 2024 reflecting the accounting updates (the “Updated Release”). A copy of the Updated Release is being furnished to the Securities and Exchange Commission (the “SEC”) as Exhibit 99.1 to this report on Form 8-K and is incorporated by reference to this Item 2.02.

    ​

    The Company filed its Annual Report on Form 10-K for the year ending December 31, 2024 (the “Form 10-K”) as of this date and the consolidated financial statements in the Form 10-K fully reflect the accounting updates.

    ​

    This Amendment amends Item 2.02 of the Original Form 8-K and the Fourth Quarter 2024 Release for the Updated Release. Except as set forth in the Updated Release, this Amendment does not modify or update any other disclosure contained in or furnished with the Original Form 8-K or the Fourth Quarter 2024 Earnings Release, which speak only as of the original issuance date and have not been updated, and this Amendment should be read in conjunction therewith.

    ​

    ***

    ​

    The information furnished pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.

    ​

    Item 7.01 Regulation FD Disclosure.

    ​

    On March 4, 2025, the Company released the Fourth Quarter 2024 Presentation. A copy of the Fourth Quarter 2024 Presentation was furnished as Exhibit 99.2 to the Original Form 8-K. The impact of the accounting updates described in Item 2.01 are reflected in the Updated Release in Exhibit 99.1 to this Amendment and is incorporated by reference to this Item 7.01.

    ​

    This Amendment amends Item 7.01 of the Original Form 8-K and the Fourth Quarter 2024 Presentation for the Updated Release. Except as set forth in the Updated Release, this Amendment does not modify or update any other disclosure contained in or furnished with the Original Form 8-K or the Fourth Quarter 2024 Presentation, which speak only as of the original issuance date and have not been updated, and this Amendment should be read in conjunction therewith.

    ​

    ***

    ​

    The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the SEC under the Exchange Act or the Securities Act, whether made before or after the date hereof, regardless of any general incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. Except as required by law, the Company undertakes no duty or obligation to publicly update or revise the information so furnished.

    ​

    Item 9.01 Financial Statements and Exhibits.

    ​

    (d)  Exhibits

     

    Exhibit Number

     

    Description

    99.1

     

    Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    ​

    ​

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    NEURONETICS, INC.

     

     

    (Registrant)

    Date: March 27, 2025

     

    ​

     

    By:

     

    /s/ Stephen Furlong

     

     

    Name:

     

    Stephen Furlong

     

     

    Title:

     

    EVP, Chief Financial Officer and Treasurer

    ​

    ​

    ​

    Get the next $STIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO and CS Macan William Andrew sold $816 worth of shares (609 units at $1.34), decreasing direct ownership by 0.07% to 879,525 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    3/6/26 4:29:47 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    EVP, CLO and CS Macan William Andrew sold $4,626 worth of shares (3,427 units at $1.35), decreasing direct ownership by 0.39% to 880,134 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    2/27/26 4:34:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    President and CEO Sullivan Keith J sold $11,410 worth of shares (8,452 units at $1.35), decreasing direct ownership by 0.55% to 1,524,713 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    2/27/26 4:33:47 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    SEC Filings

    View All

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    3/2/26 4:30:18 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    2/25/26 4:45:12 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Neuronetics Inc.

    144 - Neuronetics, Inc. (0001227636) (Subject)

    2/12/26 3:12:29 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/13/24 5:02:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    9/6/24 5:05:03 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    8/30/24 5:15:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    10/13/21 12:25:53 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Neuronetics Appoints New Chief Financial Officer

    Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company's new Chief Financial

    7/15/25 7:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

    MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

    6/2/25 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-se

    10/21/25 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care